- POAI
subsidiary announces new media for growing ovarian tumors in lab
- Using
new product, TumorGenesis partners have identified 25 cell types from
ovarian cancers
- New
media available as cell-culture market expected to reach $2.3 billion by
2024
Predictive Oncology Inc. (NASDAQ: POAI), a leader in the
cancer precision-medicine field, along with its subsidiary TumorGenesis Inc.,
has announced an innovative special media for growing ovarian tumors; the
companies have also selected US Biological Corporation as a manufacturer and
distributor of the groundbreaking media (http://ibn.fm/QjW3K). POAI anticipates the new
formulations, which will be developed in a lab, will speed discovery of biomarkers
and precision therapies.
“Using these proprietary media, our partners have identified
25 cell types from ovarian tumors, which to a large degree have never been
screened or studied by researchers,” TumorGenesis President Richard
Gabriel stated in a news release. “The resulting cells have a 95+% match to
cells found in patient bodies.”
The timing of POAI’s announcement couldn’t be better.
Experts predict that the global cell-culture media market will reach $2.3
billion by 2024. That growth – a steady 8.4% CAGR – is primarily fueled by the
increased use of biological-based drugs such as immune therapies, a space where
POAI and its subsidiaries are establishing themselves as both leaders and
pioneers.
POAI anticipates that the new media will be available Q1
2020 through Massachusetts-based US Biological, a primary brand for the
life-science industry. United States Biological’s biochemicals, antibodies,
recombinant proteins, cell-culture media and molecular biology kits are used in
virtually all scientific applications and settings including genomic research,
biotechnology, pharmaceutical development and the diagnosis of disease.
Traditionally, cell-culture media selects for only one or
two fast-growing cell types, so the ability to identify 25 different cell types
is a significant advancement. The proprietary media developed by TumorGenesis
are designed specifically to assist researchers in isolating and maintaining
the unique histological and basic biological signatures of heterogeneous
ovarian cell types while growing them in the laboratory.
“We believe by helping researchers develop cells and tumors
that more closely mimic cells and tumors found in patient bodies, we can help
lower the cost and speed the discovery of drugs and therapies that will approve
patient outcomes,” said Gabriel. Acknowledging that specialty media comprises
only a small subset of the market, Gabriel explained that TumorGenesis sees
this initial ovarian-specific formulation as the first in what the company
anticipates being a long line of tools and services it will offer to cancer
researchers.
POAI is bringing precision medicine, or tailored
medical treatment using the individual characteristics of each patient, to the
treatment of cancer. Through its Helomics division, the company leverages its
unique, clinically validated patient derived (PDx) smart tumor profiling
platform to provide oncologists with a road map to help individualize therapy.
In addition, the company is leveraging artificial intelligence and its
proprietary database of over 150,000 cancer cases tumors to build
AI-driven models of tumor drug repose to improve outcomes for the patients of
today and tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment